KDM4E

Lysine-specific demethylase 4E · B2RXH2 · KDM4E on Sugi Atlas →

5,265,040 patent compounds predicted against KDM4E, 2,509,352 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Aspirin (SCHEMBL1353)	1.00	11/20
SCHEMBL3446	0.62	11/20
Meclocycline (SCHEMBL3445)	0.59	11/20
Ampicillin (SCHEMBL3526)	1.00	10/20
SCHEMBL4015	0.73	10/20
Methacycline (SCHEMBL4014)	0.70	10/20
Methacycline (SCHEMBL4016)	0.70	10/20
Reserpine (SCHEMBL2589)	1.00	9/20
Amoxicillin (SCHEMBL3427)	1.00	9/20
Amoxicillin (SCHEMBL3428)	1.00	9/20
Iodoquinol (SCHEMBL3460)	1.00	9/20
Carbenicillin (SCHEMBL3375)	0.77	9/20
Doxycycline Anhydrous (SCHEMBL3156)	0.69	9/20
Doxycycline Anhydrous (SCHEMBL3155)	0.68	9/20
Salicylic Acid (SCHEMBL3960)	0.61	9/20
Salicylic Acid (SCHEMBL3468)	0.59	9/20
Trioxsalen (SCHEMBL1252)	1.00	8/20
Aminosalicylic Acid (SCHEMBL2262)	1.00	8/20
Epinephrine (SCHEMBL3814)	1.00	8/20
Racepinephrine (SCHEMBL3815)	1.00	8/20

Clinical trials — most relevant to KDM4E by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans	nan	ACTIVE_NOT_RECRUITING
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
MIF Involvement in AML	nan	ACTIVE_NOT_RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KDM4E binder may also engage these)

Protein	Name	Similarity
A1A5Q5	—	1.000	A1A5Q5 →
A0A1W2PPD8	—	1.000	A0A1W2PPD8 →
Q3U2K5	—	1.000	Q3U2K5 →
KDM4D	Lysine-specific demethylase 4D	0.998	landscape →
Q9V333	—	0.996	Q9V333 →
KDM5D	Lysine-specific demethylase 5D	0.994	landscape →
KDM4B	Lysine-specific demethylase 4B	0.994	landscape →
KDM5B	Lysine-specific demethylase 5B	0.993	landscape →
Q9D5Z5	—	0.993	Q9D5Z5 →
Q9V6L0	—	0.993	Q9V6L0 →
Q5XUN4	—	0.993	Q5XUN4 →
Q8VCD7	—	0.992	Q8VCD7 →
Q61T02	—	0.991	Q61T02 →
Q62240	—	0.991	Q62240 →
Q5F3R2	—	0.991	Q5F3R2 →
Q8BMD7	—	0.990	Q8BMD7 →
Q28314	—	0.990	Q28314 →
Q8BW72	—	0.990	Q8BW72 →
Q91VY5	—	0.990	Q91VY5 →
Q8L7T6	—	0.989	Q8L7T6 →
Q6IQX0	—	0.989	Q6IQX0 →
Q5RD88	—	0.989	Q5RD88 →
Q8BJM7	—	0.989	Q8BJM7 →
P41230	—	0.989	P41230 →
Q80Y84	—	0.989	Q80Y84 →
Q5TKR9	—	0.989	Q5TKR9 →
Q9VMJ7	—	0.989	Q9VMJ7 →
A0A0R4IKJ1	—	0.989	A0A0R4IKJ1 →
P03177	—	0.988	P03177 →
Q4VC12	—	0.988	Q4VC12 →